About Traxion Therapeutics
Traxion Therapeutics Inc. is a biotech company focused on the development of drugs for the treatment of intractable pain, specifically neuropathic pain. Traxion has assembled a portfolio of small molecule products to address this market opportunity. These products use more selective, mechanism-based approaches which exploit recent scientific discoveries in order to develop what Traxion believes are more effective, better tolerated treatments for neuropathic pain.
Missing: Traxion Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Traxion Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Traxion Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Traxion Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Traxion Therapeutics Frequently Asked Questions (FAQ)
When was Traxion Therapeutics founded?
Traxion Therapeutics was founded in 2005.
Where is Traxion Therapeutics's headquarters?
Traxion Therapeutics's headquarters is located at 1450 South Rolling Road, Baltimore.
What is Traxion Therapeutics's latest funding round?
Traxion Therapeutics's latest funding round is Other Investors.
Who are the investors of Traxion Therapeutics?
Investors of Traxion Therapeutics include Challenge Investment Program and Emerging Technology Center.
Who are Traxion Therapeutics's competitors?
Competitors of Traxion Therapeutics include Affibody, Molmed, KemPharm, TheraVasc, ugichem and 11 more.
Compare Traxion Therapeutics to Competitors
Cognetix is a biopharmaceutical company that is developing peptide therapeutics for the treatment of epilepsy, pain and anesthesia. The company's research and development efforts are focused on conopeptides which are peptides derived from the venom of predatory sea snails. Per the company, Cognetix has corporate collaborations in place with Medtronic, Inc. and Elan Corporation plc.
TheraVasc is a privately-held biotechnology company with offices in Louisiana, focused on the development of vascular therapies with decreased risks through the repositioning of drugs with known safety profiles. The Company's first program is for the treatment of peripheral artery disease (PAD). PAD is a chronic disorder associated with reduced blood flow to the extremities, affecting some 14 million Americans and hundreds of millions of people across the world. This disease causes severe pain in the extremities, limiting mobility and in some cases, leads to death. Unfortunately, there are no treatments available for this disease. TheraVasc's lead product, TV1001i, selectively increases blood flow in ischemic tissues affected in PAD.
Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's core technology is based on research which showed that in many neuropathic pain conditions, the signal that triggers pain actually arises at the level of the skin. This finding provides a strong biological rationale for developing topically delivered drugs to target the pain at the source - the pain receptors in the skin. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain. ARC-4558 is a topical 0.1% clonidine gel being developed for the treatment of painful diabetic neuropathy (PDN). It is a clear, water-based, fast-drying gel that provides pain relief that rivals approved oral drugs. ARC-4558 has a minimal side-effect profile with low/undetectable systemic levels of clonidine with over 600 patients treated in clinical trials to date.
ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a high proportion of common surgical procedures causing pain and dysfunction in millions of patients worldwide.
CELLective Dx is an early-stage company developing a new generation of diagnostic tools for cancer based on analysis of CTCs directly from a patient's blood. Our novel proprietary technologies combine microfluidics, flow dynamics, cell biology, molecular biology, biochemistry, and surface chemistry to capture and analyze rare CTCs in blood more rapidly and effectively than other current technologies. CELLective Dx is developing simple, rapid, blood-based cancer tests that will provide physicians and patients with accurate and individualized clinical information on disease status, treatment selection, and treatment response that will dramatically improve the clinical management of cancer.
Hunter-Fleming is a biopharmaceutical company developing new medicines to treat neurological and cardiovascular disorders. The company focus is on unmet patient needs in dementias such as Alzheimer's disease, as well as other important conditions such as neuropathic pain, head and spinal cord injuries and myocardial infarction.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.